A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

M. Gordon Joyce; Hannah A.D. King; Ines Elakhal-Naouar; Aslaa Ahmed; Kristina K. Peachman; Camila Macedo Cincotta; Caroline Subra; Rita E. Chen; Paul V. Thomas; Wei Hung Chen; Rajeshwer S. Sankhala; Agnes Hajduczki; Elizabeth J. Martinez; Caroline E. Peterson; William C. Chang; Misook Choe; Clayton Smith; Parker J. Lee; Jarrett A. Headley; Mekdi G. Taddese; Hanne A. Elyard; Anthony Cook; Alexander Anderson; Kathryn McGuckin Wuertz; Ming Dong; Isabella Swafford; James Brett Case; Jeffrey R. Currier; Kerri G. Lal; Sebastian Molnar; Manoj S. Nair; Vincent Dussupt; Sharon P. Daye; Xiankun Zeng; Erica K. Barkei; Hilary M. Staples; Kendra Alfson; Ricardo Carrion; Shelly J. Krebs; Dominic Paquin-Proulx; Nicos Karasavva; Victoria R. Polonis; Linda L. Jagodzinski; Mihret F. Amare; Sandhya Vasan; Paul T. Scott; Yaoxing Huang; David D. Ho; Natalia de Val; Michael S. Diamond; Mark G. Lewis; Mangala Rao; Gary R. Matyas; Gregory D. Gromowski; Sheila A. Peel; Nelson L. Michael; Diane L. Bolton; Kayvon Modjarrad

doi:10.1126/scitranslmed.abi5735

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

M. Gordon Joyce^*, Hannah A.D. King, Ines Elakhal-Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, Caroline Subra, Rita E. Chen, Paul V. Thomas, Wei Hung Chen, Rajeshwer S. Sankhala, Agnes Hajduczki, Elizabeth J. Martinez, Caroline E. Peterson, William C. Chang, Misook Choe, Clayton Smith, Parker J. Lee, Jarrett A. Headley, Mekdi G. TaddeseHanne A. Elyard, Anthony Cook, Alexander Anderson, Kathryn McGuckin Wuertz, Ming Dong, Isabella Swafford, James Brett Case, Jeffrey R. Currier, Kerri G. Lal, Sebastian Molnar, Manoj S. Nair, Vincent Dussupt, Sharon P. Daye, Xiankun Zeng, Erica K. Barkei, Hilary M. Staples, Kendra Alfson, Ricardo Carrion, Shelly J. Krebs, Dominic Paquin-Proulx, Nicos Karasavva, Victoria R. Polonis, Linda L. Jagodzinski, Mihret F. Amare, Sandhya Vasan, Paul T. Scott, Yaoxing Huang, David D. Ho, Natalia de Val, Michael S. Diamond, Mark G. Lewis, Mangala Rao, Gary R. Matyas, Gregory D. Gromowski, Sheila A. Peel, Nelson L. Michael, Diane L. Bolton, Kayvon Modjarrad^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (T_H1)-biased CD4 T_H response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.

Original language	English
Article number	eabi5735
Journal	Science Translational Medicine
Volume	14
Issue number	632
DOIs	https://doi.org/10.1126/scitranslmed.abi5735
State	Published - 16 Feb 2022
Externally published	Yes

Access to Document

10.1126/scitranslmed.abi5735

Cite this

Joyce, M. G., King, H. A. D., Elakhal-Naouar, I., Ahmed, A., Peachman, K. K., Cincotta, C. M., Subra, C., Chen, R. E., Thomas, P. V., Chen, W. H., Sankhala, R. S., Hajduczki, A., Martinez, E. J., Peterson, C. E., Chang, W. C., Choe, M., Smith, C., Lee, P. J., Headley, J. A., ... Modjarrad, K. (2022). A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Science Translational Medicine, 14(632), Article eabi5735. https://doi.org/10.1126/scitranslmed.abi5735

@article{065846e56d59413f8e0adc6d09d77bf8,

title = "A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates",

abstract = "The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (TH1)-biased CD4 TH response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.",

author = "Joyce, {M. Gordon} and King, {Hannah A.D.} and Ines Elakhal-Naouar and Aslaa Ahmed and Peachman, {Kristina K.} and Cincotta, {Camila Macedo} and Caroline Subra and Chen, {Rita E.} and Thomas, {Paul V.} and Chen, {Wei Hung} and Sankhala, {Rajeshwer S.} and Agnes Hajduczki and Martinez, {Elizabeth J.} and Peterson, {Caroline E.} and Chang, {William C.} and Misook Choe and Clayton Smith and Lee, {Parker J.} and Headley, {Jarrett A.} and Taddese, {Mekdi G.} and Elyard, {Hanne A.} and Anthony Cook and Alexander Anderson and {McGuckin Wuertz}, Kathryn and Ming Dong and Isabella Swafford and Case, {James Brett} and Currier, {Jeffrey R.} and Lal, {Kerri G.} and Sebastian Molnar and Nair, {Manoj S.} and Vincent Dussupt and Daye, {Sharon P.} and Xiankun Zeng and Barkei, {Erica K.} and Staples, {Hilary M.} and Kendra Alfson and Ricardo Carrion and Krebs, {Shelly J.} and Dominic Paquin-Proulx and Nicos Karasavva and Polonis, {Victoria R.} and Jagodzinski, {Linda L.} and Amare, {Mihret F.} and Sandhya Vasan and Scott, {Paul T.} and Yaoxing Huang and Ho, {David D.} and {de Val}, Natalia and Diamond, {Michael S.} and Lewis, {Mark G.} and Mangala Rao and Matyas, {Gary R.} and Gromowski, {Gregory D.} and Peel, {Sheila A.} and Michael, {Nelson L.} and Bolton, {Diane L.} and Kayvon Modjarrad",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2022",

month = feb,

day = "16",

doi = "10.1126/scitranslmed.abi5735",

language = "English",

volume = "14",

journal = "Science Translational Medicine",

issn = "1946-6234",

number = "632",

}

Joyce, MG, King, HAD, Elakhal-Naouar, I, Ahmed, A, Peachman, KK, Cincotta, CM, Subra, C, Chen, RE, Thomas, PV, Chen, WH, Sankhala, RS, Hajduczki, A, Martinez, EJ, Peterson, CE, Chang, WC, Choe, M, Smith, C, Lee, PJ, Headley, JA, Taddese, MG, Elyard, HA, Cook, A, Anderson, A, McGuckin Wuertz, K, Dong, M, Swafford, I, Case, JB, Currier, JR, Lal, KG, Molnar, S, Nair, MS, Dussupt, V, Daye, SP, Zeng, X, Barkei, EK, Staples, HM, Alfson, K, Carrion, R, Krebs, SJ, Paquin-Proulx, D, Karasavva, N, Polonis, VR, Jagodzinski, LL, Amare, MF, Vasan, S, Scott, PT, Huang, Y, Ho, DD, de Val, N, Diamond, MS, Lewis, MG, Rao, M, Matyas, GR, Gromowski, GD, Peel, SA, Michael, NL, Bolton, DL & Modjarrad, K 2022, 'A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates', Science Translational Medicine, vol. 14, no. 632, eabi5735. https://doi.org/10.1126/scitranslmed.abi5735

TY - JOUR

T1 - A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

AU - Joyce, M. Gordon

AU - King, Hannah A.D.

AU - Elakhal-Naouar, Ines

AU - Ahmed, Aslaa

AU - Peachman, Kristina K.

AU - Cincotta, Camila Macedo

AU - Subra, Caroline

AU - Chen, Rita E.

AU - Thomas, Paul V.

AU - Chen, Wei Hung

AU - Sankhala, Rajeshwer S.

AU - Hajduczki, Agnes

AU - Martinez, Elizabeth J.

AU - Peterson, Caroline E.

AU - Chang, William C.

AU - Choe, Misook

AU - Smith, Clayton

AU - Lee, Parker J.

AU - Headley, Jarrett A.

AU - Taddese, Mekdi G.

AU - Elyard, Hanne A.

AU - Cook, Anthony

AU - Anderson, Alexander

AU - McGuckin Wuertz, Kathryn

AU - Dong, Ming

AU - Swafford, Isabella

AU - Case, James Brett

AU - Currier, Jeffrey R.

AU - Lal, Kerri G.

AU - Molnar, Sebastian

AU - Nair, Manoj S.

AU - Dussupt, Vincent

AU - Daye, Sharon P.

AU - Zeng, Xiankun

AU - Barkei, Erica K.

AU - Staples, Hilary M.

AU - Alfson, Kendra

AU - Carrion, Ricardo

AU - Krebs, Shelly J.

AU - Paquin-Proulx, Dominic

AU - Karasavva, Nicos

AU - Polonis, Victoria R.

AU - Jagodzinski, Linda L.

AU - Amare, Mihret F.

AU - Vasan, Sandhya

AU - Scott, Paul T.

AU - Huang, Yaoxing

AU - Ho, David D.

AU - de Val, Natalia

AU - Diamond, Michael S.

AU - Lewis, Mark G.

AU - Rao, Mangala

AU - Matyas, Gary R.

AU - Gromowski, Gregory D.

AU - Peel, Sheila A.

AU - Michael, Nelson L.

AU - Bolton, Diane L.

AU - Modjarrad, Kayvon

PY - 2022/2/16

Y1 - 2022/2/16

N2 - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (TH1)-biased CD4 TH response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.

AB - The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019. We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50-μg) SpFN vaccine, given twice 28 days apart, induced a T helper cell 1 (TH1)-biased CD4 TH response and elicited neutralizing antibodies against SARS-CoV-2 wild type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates after high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates support the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.

UR - http://www.scopus.com/inward/record.url?scp=85124803256&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.abi5735

DO - 10.1126/scitranslmed.abi5735

M3 - Article

C2 - 34914540

AN - SCOPUS:85124803256

SN - 1946-6234

VL - 14

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 632

M1 - eabi5735

ER -

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

Abstract

Access to Document

Fingerprint

Cite this